David,
Real quick, cause that's all I have time for:
<<At least we might have gotten a quick write-up from a broke>>
She did not want this at all. At the AGM she made it clear that the company who will be covering us in the US wants their coverage to be fresh. That is the reason I suspect there was no coverage.
Also (and more importantly in this particular case), because these guys short the stock to acquire shares, it is not in their best interests to have the price go up. The more it goes down, the more shares they can acquire/dollar that REK needed.
<<What's the likelihood that the patent will be extended in the various markets?>>
Extremely good. I think they will get at least two years and if they have the product approved for uses other than O/A that can be extended much more. I think that is the route they will take -- likely for soft tissue injury (just my guess).
<<Also, I'm not clear on where they are with WF10 trials, can anyone explain that?>>
They are collecting the data. Because Oxo ran out of $, the data collection process fell behind. My own guess is that we will not see any numbers from them for 2-3 months, maybe longer. That is based on historical capacity meeting timelines, more that anything else. I predicted data much earlier than this previously, but that was before I knew about the above.
<<What's the status of the toe fungus project?>>
I think we will see this farmed out to our partner. DMX have gathered enough data to show that they can penetrate the nail with an anti-fungal. Apparently they have chosen which anti-fungal is the best (that will be based on molecular properties of the anti-fungal molecule as much as anything else).
Hope that helps,
MB |
